首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS
【24h】

Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS

机译:通过UPLC-MS / MS的抗结核剂,乙胺醇,吡嗪酰胺,利福平和利福拉脲的快速和高敏感量化

获取原文
获取原文并翻译 | 示例
           

摘要

With the increased cases of multidrug- or rifampicin-resistant tuberculosis and co-infection with HIV globally, it is difficult to achieve ideal clinical responses because of poor drug absorption and drug-drug interactions. Herein, a bioanalytical UPLC-MS/MS method was developed and validated to quantify five anti-TB agents in human plasma samples for detecting blood drug concentrations to improve therapeutic effects. To overcome the matrix effects, stable isotope labeled analogue of each analyte was used for internal standardization. A simple single-step protein precipitation by acetonitrile was employed for the sample preparation, then the analytes including rifampicin, rifabutin, pyrazinamid, ethambutol, isoniazid and their isotope labeled internal standards (ILISs) were implemented on an HILIC silica column with a gradient mode. The linear range for each analyte was covering the peak drug concentration (C-max) in the 20 times diluted plasma samples. The coefficient of variation of intra- and inter-day precision was less than 17.0 %, and the accuracy ranged between 91.5 and 110.0 %. The extraction recoveries of all agents were >= 90.2 %, and the matrix effects with internal standard-normalization for all agents were 97.1-110.0 %. The optimal blood sampling time was designed basing on the results of stability validation. This UPLC-MS/MS method with a run time of 3.5 min was successfully applied to routine therapeutic monitoring of the five anti-TB agents in patient plasma. (C) 2019 Elsevier B.V. All rights reserved.
机译:随着多药物或利福平的结核病和全球艾滋病毒的共感染的增加,由于药物吸收不良和药物 - 药物相互作用,难以实现理想的临床反应。在此,开发生物分析UPLC-MS / MS方法并验证以定量人血浆样品中的五种抗结核剂,用于检测血液药物浓度以改善治疗效果。为了克服基质效应,使用每个分析物的标记的稳定同位素用于内部标准化。采用乙腈的简单的单步蛋白沉淀用于样品制备,然后在具有梯度模式的HILIC硅胶柱上在肝脏硅柱上实施包括利福平,利福蛋白,吡嗪酰胺,乙胺醇,异烟蛋白和其同位素的分析物。每个分析物的线性范围覆盖稀释的等离子体样品中的20倍的药物浓度(C-MAX)。内部和日间精度的变异系数小于17.0%,精度范围在91.5和110.0%之间。所有试剂的提取回收率> = 90.2%,与所有试剂的内标 - 标准化的基质效应为97.1-110.0%。最佳血液采样时间基于稳定性验证的结果。该UPLC-MS / MS方法具有3.5分钟的运行时间,以成功应用于患者血浆中五种抗TB药剂的常规治疗监测。 (c)2019 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号